Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
AKT inhibitor |
| gptkbp:administeredBy |
oral
|
| gptkbp:alsoKnownAs |
gptkb:capivasertib
|
| gptkbp:approvalYear |
2023
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_States |
| gptkbp:CASNumber |
1143532-39-1
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| https://www.w3.org/2000/01/rdf-schema#label |
AZD5363
|
| gptkbp:indication |
gptkb:cancer
prostate cancer solid tumors |
| gptkbp:mechanismOfAction |
inhibits AKT signaling pathway
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1743088
25216714 |
| gptkbp:sideEffect |
nausea
diarrhea fatigue rash hyperglycemia |
| gptkbp:target |
gptkb:AKT1
gptkb:AKT2 gptkb:AKT3 |
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:usedIn |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:AKT
|
| gptkbp:bfsLayer |
6
|